CPRX vs TLRY · P/E 18, rev $491.7M vs rev $915.5M
Catalyst Pharmaceuticals Inc (CPRX) versus Tilray Inc (TLRY) — a side-by-side from cached financials, not a winner call.
Catalyst Pharmaceuticals Inc (CPRX) is a biotechnology company listed on NASDAQ.
Tilray Inc (TLRY) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported CPRX revenue for 2024-12-31 was $491.7M. Net income was $163.9M. Revenue was up 23.5% from 2023-12-31 to 2024-12-31. CPRX currently screens at market cap $3.84B and trailing P/E 18.2.
Latest reported TLRY revenue for 2026-05-31 was $915.5M. Net income was -$121.4M. Revenue was up 11.5% from 2025-05-31 to 2026-05-31. TLRY currently screens at market cap $573.9M.
CPRX currently screens at market cap $3.84B and trailing P/E 18.2. TLRY currently screens at market cap $573.9M.
Not investment advice. Open the CPRX and TLRY stock pages for the full models.
Not investment advice.